New drug LAE102 put to the test in healthy women
NCT ID NCT06908707
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called LAE102 in 32 healthy postmenopausal women to see if it is safe and how the body processes it. Participants received either a single dose of LAE102 or a placebo. The main goal was to check for side effects, not to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
32 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Oct 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 75 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Females aged 45 to 75 years of age inclusive, at time of signing the informed consent. * Are healthy postmenopausal female participants. * Have a body mass index (BMI) within the range 20.0 - 32.0kg/m\^2 inclusive at screening. * Have follicle stimulating hormones (FSH) levels ≥40 IU/L at screening. * Have clinical laboratory test results within the normal reference range for the population. * Have venous access sufficient to allow for blood sampling and IV administration of study intervention as per the protocol and have no anticipated contradictions to receiving investigational products via SC administration * Are capable of giving informed consent. * Are willing to make themselves available for study visits for the duration of the study and are willing to follow study procedures. Exclusion Criteria: * Have a history or presence of clinically significant medical condition(s) * Have a history of any malignancy within the past 5 years. * Have hemoglobin level at screening above the upper limit normal for females. * Have a fasting serum triglyceride level of more than 500mg/dL at screening. * Have an estimated glomerular filtration rate (eGFR) less than 60mL/min/1.73m\^2 at screening. * Have an abnormal electrocardiogram (ECG) * Have an abnormal blood pressure. * Show evidence at screening of HIV or Hepatitis B or C. * Have a history of or known drug related hypersensitivity or severe allergy * Underwent major surgery within 30 days prior to study intervention administration or plan to undergo major surgery during the study. * Have used in the past 90 days or intend to use during the study any medication that may affect FSH levels. * Have used or intended to use over the counter medications, and/or herbal medicines, from 14 days or 5 half-lives (if known), whichever is longer, prior to study intervention administration until the last visit. * Received any vaccine 30 days prior to screening or plan to receive any vaccine during the study. * Have participated, are currently enrolled in, or discontinued from a clinical trial involving an investigational drug or device or off-label use of a drug or device within the last 90 days, or 5-half-lives (if known, whichever is longer), of the last administration of study drug or application of the device, or any other type of medical research judged not to be scientifically or medically compatible with this study. * Have previously completed or withdrawn from this study or any other study investigating this study intervention. * Have alcohol consumption exceeding 14 units per week, a positive alcohol test at screening or administration, a history of alcohol abuse within 1 year prior to screening, or are unable to stop alcohol consumption during the study. * Have a known or suspected history of substance abuse or test positive for drugs of abuse at screening or admission * Are smoking more than 5 cigarettes (or the equivalent of other tobacco products) per day within 90 days prior to screening or are unable to stop smoking during the study. * Have donated blood or experienced blood loss of more than 400mL within 90 days prior to screening. * Are fasting or receiving weight loss treatment within 30 days prior to administration or experiencing major changes in lifestyle. * In the opinion of the investigator or sponsor and medical monitor, are unsuitable for inclusion in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy adult female participants are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Trials
Daytona Beach, Florida, 32117, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two estradiol dosing schedules put brain effects to the test
- Can better posture strengthen the pelvic floor in osteoporosis?
- Does menopause change the 'Love Hormone'? a study investigates
- Gentle tai chi may soothe joint pain caused by breast cancer treatment
- Exercise eases menopause symptoms and boosts heart health in new study
- Botox for stress? tiny study tests the idea